Labcorp said the FDA approved PGDx elio tissue complete as a companion diagnostic for BRAF V600E and V600K mutations in melanoma, expanding access to mutation testing that guides targeted therapies. The assay is positioned for patient selection for FDA-approved BRAF inhibitors and BRAF/MEK combinations. Labcorp said the next-generation test uses high-throughput hybridization-based capture covering 505 genes and can report MSI and TMB. Labcorp highlighted a clinical success rate of 94.4% and a four-to-five day workflow, designed to be distributed to hospitals and labs rather than relying on external sample shipping. —